TARO-CLOBETASOL OINTMENT USP, 0.05% 0.05 % — DIN 02245524
CLOBETASOL PROPIONATE : 0.05 % · TARO PHARMACEUTICALS INC · OINTMENT · wholesale supply in Canada
Health Canada status: MARKETED
What is TARO-CLOBETASOL OINTMENT USP, 0.05%?
TARO-CLOBETASOL OINTMENT USP, 0.05% 0.05 % contains CLOBETASOL PROPIONATE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 02245524, held by TARO PHARMACEUTICALS INC, supplied as OINTMENT for TOPICAL administration. Health Canada currently lists it as marketed, status dated 03-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-CLOBETASOL OINTMENT USP, 0.05% used for?
Topical therapy of recalcitrant corticosteroid-responsive dermatoses, including severe cases of psoriasis (excluding widespread plaque psoriasis) and eczematous dermatitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Clobetasol cost around the world?
Clobetasol is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 6 | 103 | USD███.██ |
| Romania | max producer price | 5 | 10 | RON███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| South Africa | single exit price | 3 | 5 | ZAR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Australia | ex-manufacturer | 2 | 3 | AUD███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
134 pack listings across 28 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Clobetasol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Clobetasol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
17 holders have a Canadian DIN containing Clobetasol, across 40 DINs, of which 20 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TARO PHARMACEUTICALS INC | 5 | 5 | TARO-CLOBETASOL CREAM USP, 0.05%, TARO-CLOBETASOL OINTMENT USP, 0.05%, TARO-CLOBETASOL SHAMPOO, TARO-CLOBETASOL SPRAY, TARO-CLOBETASOL TOPICAL SOLUTION USP, 0.05% | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 3 | MYLAN-CLOBETASOL CREAM, MYLAN-CLOBETASOL OINTMENT, MYLAN-CLOBETASOL SCALP APPLICATION | Sourceable in Canada |
| TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | 3 | 3 | DERMOVATE CREAM, DERMOVATE OINTMENT, DERMOVATE SCALP APPLICATION | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 3 | TEVA-CLOBETASOL | Sourceable in Canada |
| GALDERMA CANADA INC | 3 | 2 | CLOBEX LOTION, CLOBEX SHAMPOO, CLOBEX SPRAY | Sourceable in Canada |
| DR. REDDY'S LABORATORIES CANADA INC. | 1 | 1 | REDDY-CLOBETASOL SHAMPOO | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP CLOBETASOL SPRAY | Sourceable in Canada |
| ODAN LABORATORIES LTD | 1 | 1 | ODAN CLOBETASOL SPRAY | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | SANDOZ CLOBETASOL | Sourceable in Canada |
| PHARMASCIENCE INC | 5 | 0 | PMS-CLOBETASOL, PMS-CLOBETASOL CREAM, PMS-CLOBETASOL OINTMENT, PMS-CLOBETASOL SCALP APPLICATION | No marketed DIN |
| ALTIMED PHARMA INC. | 3 | 0 | ALTI-CLOBETASOL PROPIONATE CREAM 0.05%, ALTI-CLOBETASOL PROPIONATE ONT 0.05%, ALTI-CLOBETASOL PROPIONATE SCALP APPLICATION 0.05% | No marketed DIN |
| GLAXO CANADA INC | 3 | 0 | DERMOVATE CRM 0.05%, DERMOVATE ONT 0.05%, DERMOVATE SCALP APPLICATION .05% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.05 % |
|---|---|
| Dosage form | OINTMENT |
| Route | TOPICAL |
| Pack configuration (monograph) | 15 g and 50 g tubes, and 454 g jars. |
| Storage | Store at room temperature (15° - 30°C). Do not dilute cream. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Clobetasol |
|---|---|
| ATC code | D07AD01 |
| AHFS class | 84:06.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245524 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245524 |
| Brand name | TARO-CLOBETASOL OINTMENT USP, 0.05% |
| Generic / active ingredient | CLOBETASOL PROPIONATE : 0.05 % |
| Market authorization holder | TARO PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | D07AD01 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D07AD |
| Current status | MARKETED |
| Status date | 03-Oct-2005 |
| Original market date | 2002-04-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply sparingly to affected area 2-3 times daily. Maximum 50 g/week. Use for brief periods only; discontinue if no response after 1 week or once lesion heals.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Rosacea, acne vulgaris, perioral dermatitis, perianal/genital pruritus, untreated skin infections (viral, bacterial, fungal), hypersensitivity, and children under 1 year of age.
Warnings and precautions
Avoid contact with eyes (risk of glaucoma). Extensive or prolonged use may cause adrenal suppression. Do not exceed 50 g/week. Not recommended for use with occlusive dressings.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
20 of 40 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLOBEX SHAMPOO | 0.05 % | SHAMPOO | GALDERMA CANADA INC | MARKETED | 02256371 |
| CLOBEX SPRAY | 0.05 % | SPRAY | GALDERMA CANADA INC | MARKETED | 02299739 |
| DERMOVATE CREAM | 0.05 % | CREAM | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | 02213265 |
| DERMOVATE OINTMENT | .05 % | OINTMENT | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | 02213273 |
| DERMOVATE SCALP APPLICATION | .05 % | SOLUTION | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | 02213281 |
| JAMP CLOBETASOL SPRAY | 0.05 % | SPRAY | JAMP PHARMA CORPORATION | MARKETED | 02534665 |
| MYLAN-CLOBETASOL CREAM | 0.05 % | CREAM | MYLAN PHARMACEUTICALS ULC | MARKETED | 02024187 |
| MYLAN-CLOBETASOL OINTMENT | 0.05 % | OINTMENT | MYLAN PHARMACEUTICALS ULC | MARKETED | 02026767 |
| MYLAN-CLOBETASOL SCALP APPLICATION | 0.05 % | LOTION | MYLAN PHARMACEUTICALS ULC | MARKETED | 02216213 |
| ODAN CLOBETASOL SPRAY | 0.05 % | SPRAY | ODAN LABORATORIES LTD | MARKETED | 02490706 |
2 · Same class — other molecules in ATC D07AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Clobetasol | ALTI-CLOBETASOL PROPIONATE CREAM 0.05% · ALTI-CLOBETASOL PROPIONATE ONT 0.05% · ALTI-CLOBETASOL PROPIONATE SCALP APPLICATION 0.05% · APO-CLOBETASOL SPRAY · +33 more | 40 | 20 | Yes |
| Halcinonide | HALOG CREAM 0.1% · HALOG LIQ 0.1% · HALOG ONT 0.1% | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D07AC | Amcinonide · Beclometasone · Betamethasone · Combinations Of Corticosteroids · Desoximetasone · +9 more | 159 | 41 |
| D07AB | Clobetasone · Desonide · Flumetasone · Triamcinolone | 32 | 7 |
| D07AA | Hydrocortisone · Methylprednisolone | 35 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TARO-CLOBETASOL OINTMENT USP, 0.05% called?
The same molecule, Clobetasol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DERMOVAL | Latin | Morocco |
| Dermovate | Latin | South Africa |
| Xenovate | Latin | South Africa |
| Xobet | Latin | Australia |
| Clobex | Latin | Australia |
| Dermovate scalp | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.